Target Price | $252.42 |
Price | $159.26 |
Potential | 58.50% |
Number of Estimates | 26 |
26 Analysts have issued a price target Biogen 2025 . The average Biogen target price is $252.42. This is 58.50% higher than the current stock price. The highest price target is $342.00 114.74% , the lowest is $184.00 15.53% . | |
A rating was issued by 37 analysts: 23 Analysts recommend Biogen to buy, 14 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2025 of 58.50% . Most analysts recommend the Biogen stock at Purchase. |
31 Analysts have issued a sales forecast Biogen 2024 . The average Biogen sales estimate is $9.6b . This is 4.48% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.8b 5.66% , the lowest is $9.5b 2.48% .
This results in the following potential growth metrics:
2023 | $9.4b | 0.17% |
---|---|---|
2024 | $9.6b | 2.39% |
2025 | $9.5b | 1.29% |
2026 | $9.7b | 1.96% |
2027 | $10.0b | 3.49% |
2028 | $10.2b | 1.73% |
10 Analysts have issued an Biogen EBITDA forecast 2024. The average Biogen EBITDA estimate is $3.3b . This is 21.30% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.9b 43.63% , the lowest is $2.7b 1.83% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $2.1b | 23.87% |
---|---|---|
2024 | $3.3b | 56.78% |
2025 | $3.5b | 4.02% |
2026 | $3.5b | 1.72% |
2027 | $4.3b | 21.83% |
2028 | $4.9b | 14.86% |
2023 | 22.58% | 23.74% |
---|---|---|
2024 | 34.57% | 53.12% |
2025 | 36.43% | 5.38% |
2026 | 36.35% | 0.22% |
2027 | 42.79% | 17.72% |
2028 | 48.31% | 12.90% |
13 Biogen Analysts have issued a net profit forecast 2024. The average Biogen net profit estimate is $1.8b . This is 12.81% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.4b 47.61% , the lowest is $1.6b 2.53% .
This results in the following potential growth metrics and future Net Margins:
2023 | $1.2b | 61.81% |
---|---|---|
2024 | $1.8b | 56.69% |
2025 | $2.1b | 14.72% |
2026 | $2.5b | 17.61% |
2027 | $2.8b | 15.97% |
2028 | $3.2b | 10.74% |
2023 | 12.33% | 61.74% |
---|---|---|
2024 | 18.87% | 53.03% |
2025 | 21.93% | 16.22% |
2026 | 25.30% | 15.37% |
2027 | 28.35% | 12.06% |
2028 | 30.86% | 8.85% |
13 Analysts have issued a Biogen forecast for earnings per share. The average Biogen <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $12.49 . This is 12.83% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $16.34 47.61% , the lowest is $10.79 2.53% .
This results in the following potential growth metrics and future valuations:
2023 | $7.97 | 61.81% |
---|---|---|
2024 | $12.49 | 56.71% |
2025 | $14.33 | 14.73% |
2026 | $16.85 | 17.59% |
2027 | $19.54 | 15.96% |
2028 | $21.64 | 10.75% |
Current | 14.39 | 38.32% |
---|---|---|
2024 | 12.75 | 11.40% |
2025 | 11.12 | 12.78% |
2026 | 9.45 | 15.02% |
2027 | 8.15 | 13.76% |
2028 | 7.36 | 9.69% |
Based on analysts' sales estimates for 2024, the Biogen stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 2.92 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 2.41 .
This results in the following potential growth metrics and future valuations:
Current | 3.05 | 25.61% |
---|---|---|
2024 | 2.92 | 4.25% |
2025 | 2.96 | 1.31% |
2026 | 2.90 | 1.92% |
2027 | 2.80 | 3.37% |
2028 | 2.76 | 1.70% |
Current | 2.51 | 28.91% |
---|---|---|
2024 | 2.41 | 4.29% |
2025 | 2.44 | 1.30% |
2026 | 2.39 | 1.92% |
2027 | 2.31 | 3.37% |
2028 | 2.27 | 1.70% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.